Skip to main content
. 2010 Feb;12(2):173–180. doi: 10.1093/neuonc/nop041

Table 1.

Patients characteristics at time of serum sampling

Astrocytic tumors Oligodendroglial tumors
Number of patients 41 29
Tumor grade
 WHO II 14 (48%)
 WHO III 12 (29%) 15 (52%)
 WHO IV 29 (71%)
Gender
 Male 26 (63%) 14 (48%)
 Female 15 (37%) 15 (52%)
Age (y)
 Median (range) 58 (19–76) 42.7 (28–68)
Surgical procedure
 Craniotomy 28 (68%) 15 (52%)
 Stereotactic biopsy 8 (20%) 5 (17%)
 Not specified 5 (12%) 9 (31%)
KPS
 Median (range) 75% (40%–90%) (n = 34) 90% (60%–100%) (n = 26)
Preoperative MRI
 Contrast enhancement 30 (73%) 12 (45%)
 No enhancement 6 (15%) 8 (28%)
 Not specified 5 (12%) 8 (28%)
Interval between surgery and serum sampling (mos)
 Median (range) 1 (0.5–158) 1 (0.5–168)
Treatment at time of serum sampling
 Postsurgery pre-RT 24 (59%) 4 (14%)
 Ongoing RT 3 (7%) 1 (3%)
 Ongoing chemotherapy 5 (12%) 1 (3%)
 Surveillance 13 (45%)
 Not reported 9 (22%) 10 (34%)

KPS, Karnofsky performance status; RT, radiotherapy.